Asia-Pacific Gastroparesis Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Idiopathic, Diabetic, Post-Surgical, and Others), Drug Class (Prokinetic Agents, Botulinum Toxin Injections, and Antiemetic Agents), and Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Others)

Code: TIPRE00024820 | Pages: 109 | Industry: Pharmaceuticals | Date: Sep 2021
Covid

Market Introduction

APAC includes countries such as China, Japan, India, Australia, South Korea, and Rest of APAC. This region accounted for over fastest growing region of the global Gastroparesis market in 2019 owing to the large diabetic patient population, increasing number of research studies, growing government support, and increasing number of startups, pharmaceutical and biotech companies in this region. Gastroparesis (Gp) is a chronic disease with clinical symptoms of early satiety, nausea, bloating, vomiting, and abdominal pain. The rest of APAC Gastroparesis market is attributed to rising webinar, research studies and conferences in gastroparesis market. For instance, in April 2019, the Philippines Medical Association has conducted webinar on “Diabetic Gastroparesis and GI concerns in Diabetes “. Moreover, in November 2020, Journal of Neurogastroenterology and Motility, published a report on Knowledge, Attitude, and Practice Survey of Gastroparesis in Asia by Asian Neurogastroenterology and Motility Association Running Title: Gastroparesis in Asia. The Singapore, Philippines, South Korea, Taiwan, Thailand Vietnam) participated in the survey. Thus, the factors is likely to boost the gastroparesis market in forecast year.

Countries in APAC are facing challenges due to increasing incidences of COVID-19. The outbreak has severely affected the pharmaceutical industry and imposed supply chain disruptions; moreover, low-income countries face additional challenges due to the shortage of healthcare infrastructure, decreasing in demand of gastroparesis drugs such as prokinetic agents, botulinum toxin injection, antiemetic agents, and others. Moreover, the governments have preferred to continue to permit business operations and economic activities. Thus, the supply of the consumer health products or over the counter drug such as anti-emetic and prokinetic is less affected. For instance, India is among the largest hub for pharmaceutical manufacturing. The country contributes to the majority shares of supplies generic and branded drugs world-wide. The manufacturers are operating with full capacity. Thus, it is expected to maintain the demand and supply of the products in the associated markets. The outbreak has severely affected the pharmaceutical industry ad-imposed supply chain disruptions; moreover, low-income countries face additional challenges due to the shortage of healthcare infrastructure. Restrictive measures have been put forth in South Korea, Malaysia, Singapore, the Philippines, and India to prevent disease transmission.                  


Get more information on this report :



Market Overview and Dynamics

The gastroparesis market in APAC is expected to grow from US$ 1,164.94 million in 2020 to US$ 1,623.77 million by 2027; it is estimated to grow at a CAGR of 4.9% from 2020 to 2027. Diabetes mellitus is a life-threatening chronic disease mainly caused by the body’s inability to produce insulin or effectively utilize it. Diabetes is one of the health emergencies of the 21st century. According to a report published by International Diabetes Federation (IDF) in 2019, 1 in 11 people in the world are suffering from diabetes. In addition, the National Institutes of Health (NIH) also reported that the incidence of type 1 diabetes is increasing rapidly, and the disease is affecting a significant number of children and teenagers. Diabetes is one of the prominent known causes of gastroparesis. The condition is characterized by damaged nerves, especially involving vagus nerves and stomach wall cells. The damage to vagus nerves affects muscle motility of stomach and small intestine.       

Key Market Segments

The APAC gastroparesis market is segmented on the basis of type, drug class, distribution channel, and country. The APAC gastroparesis market, by type, is segmented into idiopathic, diabetic, post-surgical, and others. The idiopathic segment held the largest share of the market in 2019. The APAC gastroparesis market, by drug class type, is segmented into prokinetic agents, botulinum toxin injection, and antiemetic agents. The prokinetic agents segment held the largest share of the market in 2019. Based on distribution channel, the APAC gastroparesis market is segmented into retail pharmacies, hospital pharmacies, and others. The hospital pharmacies segment held the largest share of the market in 2019. Based on country, the APAC gastroparesis market is segmented into Australia, China, India, Japan, South Korea, and rest of APAC. Japan held the largest market share in 2019.     

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the gastroparesis market in APAC are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Allergan Plc; Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.); Ipca Laboratories Ltd.; Johnson and Johnson Services, Inc.; Pfizer Inc.; and TEVA PHARMACEUTICAL INDUSTRIES LTD.         

Reasons to buy report

  • To understand the APAC gastroparesis market landscape and identify market segments that are most likely to guarantee a strong return.
  • Stay ahead of the race by comprehending the ever-changing competitive landscape for APAC gastroparesis market.
  • Efficiently plan M&A and partnership deals in APAC gastroparesis market by identifying market segments with the most promising probable sales.
  • Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form APAC gastroparesis market.
  • Obtain market revenue forecast for market by various segments from 2021-2028 in APAC region.

APAC Gastroparesis Market Segmentation

APAC Gastroparesis Market - By Type

  • Idiopathic
  • Diabetic
  • Post-surgical
  • Others

APAC Gastroparesis Market - By Drug Class

  • Prokinetic Agents
  • Botulinum Toxin Injections
  • Antiemetic Agent

APAC Gastroparesis Market – By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

APAC Gastroparesis Market - By Country

  • Australia   
  • China
  • India
  • Japan
  • South Korea
  • Rest of APAC

APAC Gastroparesis Market - Company Profiles

  • Allergan Plc
  • Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.)
  • Ipca Laboratories Ltd.
  • Johnson and Johnson Services, Inc.
  • Pfizer Inc.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD 
 

1.           Introduction

1.1         Scope of the Study

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        APAC Gastroparesis Market – By Type

1.3.2        APAC Gastroparesis Market – By Drug Class Type

1.3.3        APAC Gastroparesis Market – By Distribution Channel

1.3.4        APAC Gastroparesis Market – By Country

2.           APAC Gastroparesis Market – Key Takeaways

3.           Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           APAC Gastroparesis Market – Market Landscape

4.1         Overview

4.2         APAC PEST Analysis

4.3         Expert Opinion

5.           APAC Gastroparesis Market – Key Market Dynamics

5.1         Market Drivers

5.1.1        Diabetes Mellitus is Becoming More Common

5.1.2        Geriatric Population is Growing

5.2         Market Restraints

5.2.1        Adverse Effects of Gastroparesis Drugs

5.3         Market Opportunities

5.3.1        Research Funding on Rise

5.4         Future Trends

5.4.1        High Focus on Gastric Electrical Stimulation Therapy Research

5.5         Impact Analysis

6.           Gastroparesis Market – APAC Analysis

6.1         APAC Gastroparesis Market Revenue Forecast and Analysis

7.           APAC Gastroparesis Market Analysis – By Type

7.1         Overview

7.2         APAC Gastroparesis Market Revenue Share, by Type (2019 and 2027)

7.3         Idiopathic

7.3.1        Overview

7.3.2        Idiopathic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

7.4         Diabetic

7.4.1        Overview

7.4.2        Diabetic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

7.5         Post-Surgical

7.5.1        Overview

7.5.2        Post-Surgical: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

7.6         Others

7.6.1        Overview

7.6.2        Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

8.           APAC Gastroparesis Market Analysis – By Drug Class Type

8.1         Overview

8.2         APAC Gastroparesis Market Revenue Share, by Drug Class Type (2019 and 2027)

8.3         Prokinetic Agents

8.3.1        Overview

8.3.2        Prokinetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

8.4         Botulinum Toxin Injection

8.4.1        Overview

8.4.2        Botulinum Toxin Injection: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

8.5         Antiemetic Agents

8.5.1        Overview

8.5.2        Antiemetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

9.           APAC Gastroparesis Market Analysis – By Distribution Channel

9.1         Overview

9.2         APAC Gastroparesis Market Share, by Distribution Channel, 2019 and 2027, (%)

9.3         Retail Pharmacies

9.3.1        Overview

9.3.2        Retail Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

9.4         Hospital Pharmacies

9.4.1        Overview

9.4.2        Hospital Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

9.5         Others

9.5.1        Overview

9.5.2        Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

10.        APAC Gastroparesis Market – Country Analysis

10.1      Overview

10.1.1     APAC: Gastroparesis Market, by Country, 2019 & 2027 (%)

10.1.2     China: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)

10.1.2.1       China: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)

10.1.2.2       China Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)

10.1.2.3       China Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)

10.1.2.4       China Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

10.1.3     Japan: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)

10.1.3.1       Japan: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)

10.1.3.2       Japan Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)

10.1.3.3       Japan Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)

10.1.3.4       Japan Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

10.1.4     India: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)

10.1.4.1       India: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)

10.1.4.2       India Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)

10.1.4.3       India Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)

10.1.4.4       India Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

10.1.5     South Korea: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)

10.1.5.1       South Korea: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)

10.1.5.2       South Korea Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)

10.1.5.3       South Korea Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)

10.1.5.4       South Korea Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

10.1.6     Australia: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)

10.1.6.1       Australia: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)

10.1.6.2       Australia Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)

10.1.6.3       Australia Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)

10.1.6.4       Australia Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

10.1.7     Rest of APAC: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)

10.1.7.1       Rest of APAC: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)

10.1.7.2       Rest of APAC Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)

10.1.7.3       Rest of APAC Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)

10.1.7.4       Rest of APAC Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

11.        Impact of COVID-19 Pandemic on APAC Gastroparesis Market

11.1      APAC: Impact Assessment of COVID-19 Pandemic

12.        Gastroparesis Market –Industry Landscape

12.1      Overview

12.2      Growth Strategies in the Gastroparesis Market, 2018-2020

12.3      Inorganic Growth Strategies

12.3.1     Overview

12.4      Organic Growth Strategies

12.4.1     Overview

13.        Company Profiles

13.1      Allergan Plc.

13.1.1     Key Facts

13.1.2     Business Description

13.1.3     Products and Services

13.1.4     Financial Overview

13.1.5     SWOT Analysis

13.1.6     Key Developments

13.2      Bausch Health Companies Inc. (Salix Pharmaceuticals)

13.2.1     Key Facts

13.2.2     Business Description

13.2.3     Products and Services

13.2.4     Financial Overview

13.2.5     SWOT Analysis

13.2.6     Key Developments

13.3      Johnson and Johnson Services, Inc.

13.3.1     Key Facts

13.3.2     Business Description

13.3.3     Products and Services

13.3.4     Financial Overview

13.3.5     SWOT Analysis

13.3.6     Key Developments

13.4      TEVA PHARMACEUTICAL INDUSTRIES LTD

13.4.1     Key Facts

13.4.2     Business Description

13.4.3     Products and Services

13.4.4     Financial Overview

13.4.5     SWOT Analysis

13.4.6     Key Developments

13.5      Pfizer Inc.

13.5.1     Key Facts

13.5.2     Business Description

13.5.3     Products and Services

13.5.4     Financial Overview

13.5.5     SWOT Analysis

13.5.6     Key Developments

13.6      Ipca Laboratories Ltd

13.6.1     Key Facts

13.6.2     Business Description

13.6.3     Products and Services

13.6.4     Financial Overview

13.6.5     SWOT Analysis

13.6.6     Key Developments

14.        Appendix

14.1      About the Insight Partners

14.2      Glossary of Terms

LIST OF TABLES

Table 1.             China Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 2.             China Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)

Table 3.             China Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 4.             Japan Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 5.             Japan Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)

Table 6.             Japan Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 7.             India Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 8.             India Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)

Table 9.             India Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 10.          South Korea Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 11.          South Korea Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)

Table 12.          South Korea Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 13.          Australia Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 14.          Australia Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)

Table 15.          Australia Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 16.          Rest of APAC Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 17.          Rest of APAC Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)

Table 18.          Rest of APAC Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 19.          Recent Inorganic Growth Strategies in the Gastroparesis market

Table 20.          Glossary of Terms, Gastroparesis Market

LIST OF FIGURES

Figure 1.           APAC Gastroparesis Market Segmentation

Figure 2.           APAC Gastroparesis Market Segmentation, By Country

Figure 3.           APAC Gastroparesis Market Overview

Figure 4.           Idiopathic Segment Held Largest Share of APAC Gastroparesis Market

Figure 5.           India to Show Remarkable Growth During Forecast Period

Figure 6.           APAC PEST Analysis

Figure 7.           APAC Gastroparesis Market Impact Analysis of Drivers and Restraints

Figure 8.           APAC Gastroparesis Market – Revenue Forecast And Analysis – 2019- 2027

Figure 9.           APAC Gastroparesis Market Revenue Share, by Type (2019 and 2027)

Figure 10.        APAC Idiopathic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

Figure 11.        APAC Diabetic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

Figure 12.        APAC Post-Surgical: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

Figure 13.        APAC Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

Figure 14.        APAC Gastroparesis Market Revenue Share, by Drug Class Type (2019 and 2027)

Figure 15.        APAC Prokinetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

Figure 16.        APAC Botulinum Toxin Injection: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

Figure 17.        APAC Antiemetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

Figure 18.        APAC Gastroparesis Market Share, by Distribution Channel, 2019 and 2027 (%)

Figure 19.        APAC Retail Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

Figure 20.        APAC Hospital Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

Figure 21.        APAC Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

Figure 22.        APAC: Gastroparesis Market, by Key Country – Revenue (2019) (USD Million)

Figure 23.        China: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)

Figure 24.        Japan: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)

Figure 25.        India: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)

Figure 26.        South Korea: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)

Figure 27.        Australia: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)

Figure 28.        Rest of APAC: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)

Figure 29.        Impact of COVID-19 Pandemic on Gastroparesis Market in APAC Countries

Figure 30.        Growth Strategies in the Gastroparesis Market, 2018-2020

  1. Allergan Plc
  2. Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.)
  3. Ipca Laboratories Ltd.
  4. Johnson and Johnson Services, Inc.
  5. Pfizer Inc.
  6. TEVA PHARMACEUTICAL INDUSTRIES LTD
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the APAC gastroparesis market
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The key findings and recommendations highlight crucial progressive industry trends in the APAC gastroparesis market, thereby allowing players across the value chain to develop effective long-term strategies
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
  • Scrutinize in-depth APAC market trends and outlook coupled with the factors driving the gastroparesis market, as well as those hindering it
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Related Tags Asia-Pacific Gastroparesis Market Asia-Pacific Gastroparesis Market Research Asia-Pacific Gastroparesis Market Insight Asia-Pacific Gastroparesis Market Trends Asia-Pacific Gastroparesis Market Forecast Asia-Pacific Gastroparesis Market Share Asia-Pacific Gastroparesis Market 2027 Asia-Pacific Gastroparesis Market Growth Asia-Pacific Gastroparesis Industry Sector Asia-Pacific Gastroparesis PDF Report Asia-Pacific Gastroparesis Analysis Asia-Pacific Gastroparesis Research Competitive Analysis

Purchase Options
Single User License
$3000
Site License
$4000
Enterprise License
$5000